Compare XMTR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | SYRE |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2021 | 2016 |
| Metric | XMTR | SYRE |
|---|---|---|
| Price | $62.91 | $30.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $55.11 | ★ $56.50 |
| AVG Volume (30 Days) | 745.4K | ★ 792.9K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $642,780,000.00 | N/A |
| Revenue This Year | $26.71 | N/A |
| Revenue Next Year | $20.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.40 | N/A |
| 52 Week Low | $18.59 | $10.91 |
| 52 Week High | $69.26 | $35.31 |
| Indicator | XMTR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 48.15 |
| Support Level | $59.41 | $29.60 |
| Resistance Level | $69.00 | $31.69 |
| Average True Range (ATR) | 3.23 | 1.49 |
| MACD | -0.04 | -0.61 |
| Stochastic Oscillator | 38.30 | 38.96 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.